BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 37716507)

  • 1. Somatostatin Receptor Type 2 and Thyroid-Stimulating Hormone Receptor Expression in Oncocytic Thyroid Neoplasms: Implications for Prognosis and Treatment.
    Gillis A; Zheng-Pywell R; McLeod C; Wang D; Ness JM; Guenter R; Whitt J; Prolla TA; Chen H; Gonzalez ML; Rose B; Lloyd RV; Jaskula-Sztul R; Lin D
    Mod Pathol; 2023 Dec; 36(12):100332. PubMed ID: 37716507
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Decreased expression of thyrotropin receptor gene suggests a high-risk subgroup for oncocytic adenoma.
    Mirebeau-Prunier D; Guyétant S; Rodien P; Franc B; Baris O; Rohmer V; Reynier P; Tourmen Y; Malthièry Y; Savagner F
    Eur J Endocrinol; 2004 Mar; 150(3):269-76. PubMed ID: 15012610
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thyroid-stimulating hormone receptor affects metastasis and prognosis in papillary thyroid carcinoma.
    Liu TR; Su X; Qiu WS; Chen WC; Men QQ; Zou L; Li ZQ; Fu XY; Yang AK
    Eur Rev Med Pharmacol Sci; 2016 Sep; 20(17):3582-91. PubMed ID: 27649658
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CIRCULATING THYROID-STIMULATING HORMONE RECEPTOR MESSENGER RNA AS A MARKER OF TUMOR AGGRESSIVENESS IN PATIENTS WITH PAPILLARY THYROID MICROCARCINOMA.
    Aliyev A; Gupta M; Nasr C; Hatipoglu B; Milas M; Siperstein A; Berber E
    Endocr Pract; 2015 Jul; 21(7):777-81. PubMed ID: 25786552
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Thakur S; Daley B; Millo C; Cochran C; Jacobson O; Lu H; Wang Z; Kiesewetter D; Chen X; Vasko V; Klubo-Gwiezdzinska J
    Clin Cancer Res; 2021 Mar; 27(5):1399-1409. PubMed ID: 33355247
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of sodium/iodide transporters and thyroid stimulating hormone receptors in thyroid cancer patients and its correlation with iodine nutrition status and pathology.
    Li J; Dong JN; Zhao Z; Lv Q; Yun B; Liu JQ; Cai XY
    Eur Rev Med Pharmacol Sci; 2018 Jul; 22(14):4573-4580. PubMed ID: 30058701
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Methylation status of TSHr in well-differentiated thyroid cancer by using cytologic material.
    Kartal K; Onder S; Kosemehmetoglu K; Kilickap S; Tezel YG; Kaynaroglu V
    BMC Cancer; 2015 Oct; 15():824. PubMed ID: 26519197
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of a Bridge Immunoassay with Two Bioassays for Thyrotropin Receptor Antibody Detection and Differentiation.
    Allelein S; Diana T; Ehlers M; Kanitz M; Hermsen D; Schott M; Kahaly GJ
    Horm Metab Res; 2019 Jun; 51(6):341-346. PubMed ID: 31207654
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential transcriptional and protein expression of thyroid-stimulating hormone receptor in ovarian carcinomas.
    Gyftaki R; Liacos C; Politi E; Liontos M; Saltiki K; Papageorgiou T; Thomakos N; Haidopoulos D; Rodolakis A; Alevizaki M; Bamias A; Dimopoulos A
    Int J Gynecol Cancer; 2014 Jun; 24(5):851-6. PubMed ID: 24844218
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thyroid-stimulating hormone receptor (TSHR) as a target for imaging differentiated thyroid cancer.
    Gimblet GR; Whitt J; Houson HA; Lin D; Guenter R; Rao TC; Wang D; Ness J; Gonzalez ML; Murphy MS; Gillis A; Chen H; Copland JA; Kenderian SS; Lloyd RV; Szkudlinski MW; Lapi SE; Jaskula-Sztul R
    Surgery; 2024 Jan; 175(1):199-206. PubMed ID: 37919223
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of peripheral thyrotropin receptor mRNA in follow-up of differentiated thyroid cancer.
    Milas M; Barbosa GF; Mitchell J; Berber E; Siperstein A; Gupta M
    Ann Surg Oncol; 2009 Feb; 16(2):473-80. PubMed ID: 19015922
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Importance of Somatostatin Receptor 2 (SSTR2) and Somatostatin Receptor 5 (SSTR5) Expression in Thyrotropin-Producing Pituitary Adenoma (TSHoma).
    Yu B; Zhang Z; Song H; Chi Y; Shi C; Xu M
    Med Sci Monit; 2017 Apr; 23():1947-1955. PubMed ID: 28434012
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differentiation of benign thyroid nodules from malignant thyroid nodules through miR-205-5p and thyroid-stimulating hormone receptor mRNA.
    Zhou J; Cao L; Chen Z
    Hormones (Athens); 2021 Sep; 20(3):571-580. PubMed ID: 33788150
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unraveling the significance of TSHR mutations in indeterminate thyroid cytology specimens.
    Andrianus S; Gubbiotti MA; Mandel SJ; Nikiforov YE; Baloch Z
    Diagn Cytopathol; 2023 Jul; 51(7):406-413. PubMed ID: 37042127
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of sodium-iodide symporter and TSH receptor in subclinical metastatic lymph nodes of papillary thyroid microcarcinoma.
    So YK; Son YI; Baek CH; Jeong HS; Chung MK; Ko YH
    Ann Surg Oncol; 2012 Mar; 19(3):990-5. PubMed ID: 21879263
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The utility of peripheral thyrotropin receptor mRNA in the management of differentiated thyroid cancer.
    Aliyev A; Soundararajan S; Bucak E; Gupta M; Hatipoglu B; Nasr C; Siperstein A; Berber E
    Surgery; 2015 Oct; 158(4):1089-93; discussion 1093-4. PubMed ID: 26212344
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thyroid-stimulating hormone receptor messenger ribonucleic acid measurement in blood as a marker for circulating thyroid cancer cells and its role in the preoperative diagnosis of thyroid cancer.
    Chia SY; Milas M; Reddy SK; Siperstein A; Skugor M; Brainard J; Gupta MK
    J Clin Endocrinol Metab; 2007 Feb; 92(2):468-75. PubMed ID: 17118994
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression and correlation of sodium/iodide symporter and thyroid stimulating hormone receptor in human thyroid carcinoma.
    Wang ZF; Liu QJ; Liao SQ; Yang R; Ge T; He X; Tian CP; Liu W
    Tumori; 2011; 97(4):540-6. PubMed ID: 21989446
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The potential of somatostatin receptor 2 as a novel therapeutic target in salivary gland malignant tumors.
    Meirovitz A; Shouchane-Blum K; Maly A; Bersudski E; Hirshoren N; Abrams R; Popovtzer A; Orevi M; Weinberger J
    J Cancer Res Clin Oncol; 2021 May; 147(5):1335-1340. PubMed ID: 33598797
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Loss of somatostatin receptor subtype 2 in prostate cancer is linked to an aggressive cancer phenotype, high tumor cell proliferation and predicts early metastatic and biochemical relapse.
    Hennigs JK; Müller J; Adam M; Spin JM; Riedel E; Graefen M; Bokemeyer C; Sauter G; Huland H; Schlomm T; Minner S
    PLoS One; 2014; 9(7):e100469. PubMed ID: 25010045
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.